DUBLIN–(BUSINESS WIRE)–The “Antibody Fragments Market Size, Share & Trends Analysis Report by Specificity (Monoclonal Antibodies, Polyclonal Antibodies), by Type, by Therapy, by Application, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global antibody fragments market size is expected to reach USD 11.36 billion by 2030, expanding at a CAGR of 5.9% from 2022 to 2030
There has been a steady increase in chronic conditions across the globe owing to the increasing geriatric population and societal behavior changes. The expediting urbanization is leading to the growth of the middle class resulting in people adopting a more sedentary and unhealthier lifestyle, in turn, causing an increase in diseases such as diabetes. The emerging markets are predicted to hold the largest patient burden owing to the significant population growth.
Furthermore, growing investments by the key market players have contributed to the industry growth. For instance, in June 2020, Vanderbilt University Medical Center collaborated with AstraZeneca to advance the company’s coronavirus-neutralizing antibodies into clinical development as a possible combination therapy for the treatment and prevention of COVID-19. These factors would drive the market in the coming years.
Antibodies are an important tool for molecular and protein detection. Even though whole antibodies are preferable for most immunoassay applications, the performance for some experiments is only enhanced by antibody fragments, such as F(ab’)2 and Fab.
Monoclonal antibodies are a significant class of therapeutic drugs that have received approval to treat various cancers. With more than 80 antibodies already approved for use in various disease indications, these antibodies represent the largest class of biopharmaceuticals. The introduction of smaller, antigen-binding antibody fragments has been growing at a fast pace, which is impacting the industry positively.
Antibody fragments are also anticipated to be preferred over full-chain antibodies due to their lower manufacturing and purification costs. The use of antibody fragments for the treatment of a specific disease may be constrained by strict ICD-10 rules. However, the new advancements in the clinical development of antibody fragments for serious diseases may offer significant market growth opportunities.
Antibody Fragments Market Report Highlights
- By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies
- Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb
- By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others
- By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes
- North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes
- Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments
Market Dynamics
Market driver analysis
- Increasing prevalence of infectious and chronic diseases
- Antibody fragments are preferred over other alternatives
- Increasing public-private investments for pharma and biotech research
Market restraint analysis
- Obstacles in the purification of antibody fragments
Market Segments
By Specificity, 2018 – 2030 (USD Million)
- Monoclonal Antibodies
- Polyclonal Antibodies
By Type, 2018 – 2030 (USD Million)
- FAB
- scFv
- sdAb
By Therapy, 2018 – 2030 (USD Million)
- Praxbind (idarucizumab)
- Ranibizumab (Lucentis)
- Certolizumab pegol (Cimzia)
- Iodine (1311) Metuximab/ Licartin
- Beovu (brolucizumab-dbll)
- Cablivi (caplacizumab-yhdp)
- Blinatumomab/ Blincyto
- PAB
- CroFab
- Anavip
- Anascorp
- Botulism Antitoxin Heptavalent (HBAT)
- Digibind
- DigiFab
- AFM13
- HPN-424
- MGD007
- Tebotelimab (MGD013)
- Bentracimab (PB2452)
- Flotetuzumab (MGD006)
- AK104
- Ozoralizumab
- Sonelokimab (ALX0761)
By Application, 2018 – 2030 (USD Million)
- Cancer
- Immunodeficiency
Competitive Landscape
- Pfizer Inc
- Sanofi
- Albynx
- Novartis AG
- Genentech, Inc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Lilly
For more information about this report visit https://www.researchandmarkets.com/r/2536va
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900